$-0.04
(Market cap
$2,121 Mln
Recently Viewed
Clear AllMarket cap
$2,121 Mln
Revenue (TTM)
$10,309 Mln
P/E Ratio
13.5
P/B Ratio
18.8
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$157 Mln
ROE
0.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
6.8
Debt to Equity
-38.4
Book Value
$--
EPS
$0.4
Face value
--
Shares outstanding
373,463,589
CFO
$14,715.10 Mln
EBITDA
$33,656.00 Mln
Net Profit
$-7,588.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bausch Health Companies (BHC)
| -18.1 | 13.7 | -14.4 | 20.7 | -9.6 | -28.1 | -16.2 |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Bausch Health Companies (BHC)
| -13.8 | 27.7 | -77.3 | 32.7 | -30.5 | 62.0 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bausch Health Companies (BHC)
|
5.7 | 2,121.3 | 10,309.0 | 155.3 | 17.0 | -17 | 13.5 | 18.8 |
| 4.5 | 929.6 | 14.1 | -33.5 | -264.9 | -38.5 | -- | 12.1 | |
| 3.7 | 216.4 | 363.3 | -42.5 | 0.1 | -6 | -- | 0.6 | |
| 1.2 | 512.0 | 278.4 | -326.6 | -102.3 | -52.4 | -- | 0.9 | |
| 1.6 | 168.6 | 0.0 | -33.8 | -- | -158.8 | -- | 13.0 | |
| 2.8 | 1,034.6 | 193.4 | -9.5 | -8.9 | -0.9 | -- | 0.9 | |
| 0.4 | 2.4 | 54.7 | -11.3 | -16.3 | -516.3 | -- | 0.9 | |
| 1.5 | 205.3 | 279.9 | 18.2 | -4.3 | 4.8 | 13.3 | 0.8 | |
| 3.3 | 18.5 | 0.0 | -26.6 | -- | -289.6 | -- | 2.6 | |
| 3.3 | 18.5 | 0.0 | -26.6 | -- | -289.6 | -- | 2.6 | |
| 1.5 | 391.4 | 946.4 | -15.8 | -1.2 | -1.4 | -- | 0.5 |
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic... pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada. Address: 2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8 Read more
CEO & Director
Mr. Thomas J. Appio
CEO & Director
Mr. Thomas J. Appio
Headquarters
Laval, QC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Bausch Health Companies Inc (BHC) is $5.70 (NYSE) as of 22-Apr-2026 10:44 EDT. Bausch Health Companies Inc (BHC) has given a return of -9.57% in the last 3 years.
The P/E ratio of Bausch Health Companies Inc (BHC) is 13.52 times as on 15-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
16.58
|
-4.66
|
|
2024
|
-65.18
|
-2.34
|
|
2023
|
-4.95
|
-2.87
|
|
2022
|
-10.10
|
-3.28
|
|
2021
|
-10.60
|
-295.67
|
The 52-week high and low of Bausch Health Companies Inc (BHC) are Rs 8.69 and Rs 4.41 as of 22-Apr-2026.
Bausch Health Companies Inc (BHC) has a market capitalisation of $ 2,121 Mln as on 15-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Bausch Health Companies Inc (BHC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.